SGLT2i Benefit in HFrEF: Significant and Rapidly Apparent
Physician's Weekly,
DAPA-HF analysis makes case to overcome ’clinical inertia’ For clinicians who continue to need convincing about the value of…
DAPA-HF analysis makes case to overcome ’clinical inertia’ For clinicians who continue to need convincing about the value of…
MedicalResearch.com Interview with: Dr.
Research conducted between 2007 and 2009 showed that many patients were not receiving the recommended doses of three categories…